Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The promise and challenges of immune agonist antibody development in cancer
Patrick A. Mayes, Kenneth W. Hance, Axel Hoos
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 7, pp. 509-527
Closed Access | Times Cited: 317

Showing 1-25 of 317 citing articles:

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 12, pp. 725-741
Closed Access | Times Cited: 1009
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Lukas Kraehenbuehl, Chien‐Huan Weng, Shabnam Eghbali, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 1, pp. 37-50
Closed Access | Times Cited: 588
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma, Bilal A. Siddiqui, Swetha Anandhan, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 838-857
Open Access | Times Cited: 545
Non-genetic mechanisms of therapeutic resistance in cancer
Jean‐Christophe Marine, Sarah‐Jane Dawson, Mark A. Dawson
Nature reviews. Cancer (2020) Vol. 20, Iss. 12, pp. 743-756
Closed Access | Times Cited: 442
Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development
Tao Wang, Changying Chen, Leon M. Larcher, et al.
Biotechnology Advances (2018) Vol. 37, Iss. 1, pp. 28-50
Open Access | Times Cited: 436
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Alan J. Korman, Sarah C. Garrett-Thomson, Nils Lönberg
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 7, pp. 509-528
Closed Access | Times Cited: 382
T cells in health and disease
Lina Sun, Yanhong Su, Anjun Jiao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 359
TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma
Xiaochen Wang, Qifeng He, Haiyuan Shen, et al.
Journal of Hepatology (2019) Vol. 71, Iss. 4, pp. 731-741
Closed Access | Times Cited: 238
Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy
Lili Cheng, Xiaoge Zhang, Junjie Tang, et al.
Biomaterials (2021) Vol. 275, pp. 120964-120964
Closed Access | Times Cited: 237
Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
Chunyong Ding, Zilan Song, Ancheng Shen, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 10, Iss. 12, pp. 2272-2298
Open Access | Times Cited: 232
Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors
Francesc Graus, Josep Dalmau
Nature Reviews Clinical Oncology (2019) Vol. 16, Iss. 9, pp. 535-548
Closed Access | Times Cited: 225
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Antonio Passaro, Julie R. Brahmer, Scott Antonia, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 6, pp. 598-610
Closed Access | Times Cited: 188
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Xinyi Li, Wenchen Pu, Qingquan Zheng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 188
Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
Jackson G. Egen, Wenjun Ouyang, Lawren C. Wu
Immunity (2020) Vol. 52, Iss. 1, pp. 36-54
Open Access | Times Cited: 167
Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
Rena Liu, Robert J. Oldham, Emma Teal, et al.
Antibodies (2020) Vol. 9, Iss. 4, pp. 64-64
Open Access | Times Cited: 167
Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade
Jianjun Yang, Xiguang Liu, Sai Cao, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 143
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 135
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy
Shreyas Gaikwad, Manas Yogendra Agrawal, Itishree Kaushik, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 137-150
Closed Access | Times Cited: 114
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Zhenyi Niu, Runsen Jin, Yan Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 95
Reducing affinity as a strategy to boost immunomodulatory antibody agonism
Xiaojie Yu, Christian M. Orr, H. T. Claude Chan, et al.
Nature (2023) Vol. 614, Iss. 7948, pp. 539-547
Closed Access | Times Cited: 78
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Linghui Qian, Xuefen Lin, Xue Gao, et al.
Chemical Reviews (2023) Vol. 123, Iss. 12, pp. 7782-7853
Closed Access | Times Cited: 66
Extracellular targeted protein degradation: an emerging modality for drug discovery
James A. Wells, Kaan Kumru
Nature Reviews Drug Discovery (2023) Vol. 23, Iss. 2, pp. 126-140
Closed Access | Times Cited: 65
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
Christina Claus, Claudia Ferrara, Christian Klein
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 59
Boosting Checkpoint Immunotherapy with Biomaterials
Lujie Liu, Yuanwei Pan, Chenchen Zhao, et al.
ACS Nano (2023) Vol. 17, Iss. 4, pp. 3225-3258
Closed Access | Times Cited: 59
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Lu Tang, Zhongpei Huang, Heng Mei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 59
Page 1 - Next Page

Scroll to top